Drug intelligence / Profile preview

EN-RX2

Development stage: Preclinical
Lead developer: Enedra Therapeutics

Overview

EN-RX2 is an investigational precision medicine program currently in the lead stage of preclinical development for the treatment of solid tumours. Developed by Enedra Therapeutics using their proprietary CASPAROV™ platform, EN-RX2 is designed to target specific Convergent Genomic Signatures (CGS) that identify shared therapeutic vulnerabilities across heterogeneous cancer populations. While the specific molecular target and drug modality (e.g., small molecule or biologic) have not been publicly disclosed, the program represents a core component of Enedra's pipeline focused on stratified oncology treatments.

Beyond the preview

Go deeper on EN-RX2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EN-RX2.

Explore the full profile